Atogepant
- TRADE NAME: Qulipta (AbbVie)
- INDICATIONS: Treatment of episodic migraine in adults.
- CLASS: Calcitonin gene-related peptide (CGRP) receptor antagonist
- HALF-LIFE: approximately 11 hours
FDA APPROVAL DATE: 09/28/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Cimetidine, Ciprofloxacin, Cyclosporine, CYP3A4 inducers, CYP3A4 inhibitors, Esomeprazole, Fluconazole, Grapefruit Juice, Itraconazole, Quinidine, Rifampin
No adequate data on the developmental risk associated with the use of atogepant in pregnant women.
Please login to see the rest of this drug profile
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 02/18/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric